This study examined the effects of total anatomical reconstruction (TAR) during robot-assisted radical prostatectomy on recovery of urinary continence. 

The authors determined the effect of diabetes on prostate cancer outcome following prostate surgery. 

The authors aimed to determine the effect of enzalutamide on quality of life in patients with hormone-resistant prostate cancer after chemotherapy. 

The authors aimed to determine the effect of early and delayed radiation treatment on patient outcome following prostate surgery. 

This study aimed to evaluate the complications associated with robotic-assisted prostate removal (minimally invasive) compared to an open surgical procedure (more invasive).  

This study examined stereotactic body radiotherapy (SBRT) as a treatment for advanced prostate cancer. This study concluded that SBRT may be effective in the treatment of these patients.

This article investigated the safety and effectiveness of Lutetium-177 PSMA (LuPSMA) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The authors concluded that LuPSMA is a safe and effective treatment option for these patients.

This study compared the effectiveness and safety of immunotherapy versus standard treatment options in patients with metastatic colorectal cancer (mCRC). The data showed that immunotherapy tended to improve the survival outcomes in these patients.

This study evaluated the safety and effectiveness of sipuleucel-T (Provenge) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). The authors found that the average survival after sipuleucel-T treatment was 30.7 months and that 13.7% of patients experienced side effects.

This study evaluated the long-term outcomes of docetaxel (Taxotere) plus hormone therapy for patients with metastatic prostate cancer (cancer that spread outside the prostate). This study found that this treatment combination improved survival for these patients, regardless of tumor burden.